This product is a recombinant mouse antibody that can recognize CVA10. This antibody cross-reacts with three forms of capsids and binds at a border region spanning all three viral proteins, VP1 to VP3. It exhibits high neutralizing activity in the neutralization assay in vitro.
Figure 1 Binding efficacy of NAb 2G8 evaluated with the indirect ELISA.
NAb 2G8 exhibits high binding affinities with the CVA10 particles [median effective concentration (EC₅₀) values from 83.1 to 251.1 ng/ml]. The IC₅₀ and EC₅₀ values were calculated with nonlinear regression fitting curves. The optical density (OD) value was read at A₄₅₀/₆₂₀.
Zhu, R., Xu, L., Zheng, Q., Cui, Y., Li, S., He, M., ... & Chen, Z. (2018). Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science advances, 4(9), eaat7459.
Figure 2 Neutralization assay of CVA10 NAb 2G8.
The IC₅₀ value is 0.2 μg/ml.
Zhu, R., Xu, L., Zheng, Q., Cui, Y., Li, S., He, M., ... & Chen, Z. (2018). Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science advances, 4(9), eaat7459.
Figure 3 Neutralization assay of NAb 2G8 at pre-attachment (blue line) or post-attachment (red line).
NAb 2G8 exhibits much higher neutralizing capacity at pre-attachment (IC₅₀ = 2.1 μg/ml) than at post-attachment (IC₅₀ = 22.7 μg/ml).
Zhu, R., Xu, L., Zheng, Q., Cui, Y., Li, S., He, M., ... & Chen, Z. (2018). Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science advances, 4(9), eaat7459.
Figure 4 In vivo preventive and therapeutic efficacy of NAb 2G8.
The infected mice were treated with NAb 2G8 12 hours before (blue line) or 24 hours after (red line) infection intraperitoneally with CVA10 and monitored daily after inoculation. Both experimental groups showed 100% survival rates, but 0% for two control groups.
Zhu, R., Xu, L., Zheng, Q., Cui, Y., Li, S., He, M., ... & Chen, Z. (2018). Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science advances, 4(9), eaat7459.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PFBC-309 | Recombinant Mouse Anti-CVA10 Antibody Fab Fragment (PFBC-309) | ELISA, Neut | Mouse Fab |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABC-309, RRID: AB_3111582)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.